Alliance Overview
Affymax’s business strategy is to become a fully integrated biopharmaceutical company. The company intends to develop commercial capabilities to target high potential, but concentrated, markets in the United States and utilize partnerships and collaborations to reach ex-U.S. markets.
Takeda
In 2006, Affymax, Inc. (Nasdaq: AFFY) and Takeda Pharmaceutical Company Limited (TSE: 4502) entered into an exclusive global agreement to collaborate on the development and commercialization of Affymax’s product candidate, peginesatide (formerly known as Hematide™).
If peginesatide is approved by the FDA, both companies will co-commercialize peginesatide in the U.S. with equal profit sharing regardless of indication, while Takeda will hold an exclusive license to develop and commercialize outside the U.S.
Nektar
Affymax has an agreement with Nektar which covers Nektar’s supply of PEG (polyethylene glycol) to Affymax for the production of peginesatide. The compound is PEGylated for increased stability and extended half-life.